Don S. Dizon, MD

Formulary Frontlines®

PARP Inhibitors for Ovarian Cancer: Who and When, And Can We Afford It?

07/20/2018

Sarah M Temkin, MD, and Don Dizon, MD, discuss the benefits of PARP inhibitors for treating ovarian cancer and why effectiveness, toxicity, safety, and cost must be balanced for an individual patient to determine the right PARP inhibitor for...

Sarah M Temkin, MD, and Don...

07/20/2018

First Report Managed Care

Perspectives

Leveraging Quality Measurement to Drive Equitable Cancer Care for Transgender Individuals

08/07/2023

Theresa Schmidt , MA, PMP, CSPO;

Tom Valuck , MD, JD;

Don S. Dizon , MD;

Nina Regenold , MSc;

Will Nolan ;

Elizabeth Donckels , MSPH;

Elizabeth Donckels, MSPH, and colleagues investigate several measurement tactics to promote cancer care quality improvement for transgender individuals.

Elizabeth Donckels, MSPH, and...

08/07/2023

Journal of Clinical Pathways